Shareholders approve merger of BioAlliance Pharma and Topotarget


The combined business will be renamed Onxeo after completion of the transaction

BioAlliance Pharma, a French developer of drugs for orphan oncology diseases, is to merge with Denmark-based biopharmaceutical company Topotarget after receiving shareholder approval for the deal.

The combined business aims to become a leading orphan oncology company and will be renamed Onxeo after completion.

No financial details have been revealed.

The shareholders also approved the appointment of Orfacare Consulting, represented by Bo Jesper Hansen, and of Per Samuelsson, of Healthcap, as board members of Onxeo, effective as of the completion of the merger. As previously announced, Judith Greciet will be the CEO of Onxeo and Patrick Langlois the Chairman of the Board.

Sign up for your free email newsletter

Completion is now subject to registration by the relevant French and Danish authorities, and should take place during July.